WOONSOCKET, R.I., Nov. 13, 2013 /PRNewswire/ -- MultiCell
Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a second
U.S. patent application concerning methods and formulations to
achieve targeted tumor cell death. MCT-485 is a noncoding
double stranded micro RNA (miRNA) which has demonstrated oncolytic
and immune stimulating activity in in vitro models of
hepatocellular carcinoma. MCT-485 is currently being
evaluated in animal models of hepatocellular carcinoma.
This invention addresses the need to direct the powerful
biological effect of miRNAs such as MCT-485 towards tumor cells and
away from normal tissues. This patent application describes
compositions and methods that target populations of cancerous cells
which have an enhanced capability to mediate the process of
relapse, progression and metastasis. Not all cancer cells
have a tumor initiating capability; this U.S. patent application
describes compositions and methods that target cancer by delivering
a biologically active, cytotoxic payload of miRNA to only those
cells having the highest tumor initiating capability that are part
of the cancerous process such as cancer stem cells and tumor
initiating cells, and to kill those cells without killing cells not
directly involved in the process of relapse, progression and
metastasis of cancer.
Hepatocellular carcinoma is the most common form of primary
liver cancer, and is a leading cause of cancer death worldwide.
Over 1 million cases of hepatocellular carcinoma are reported
annually. Current approaches for treatment of hepatocellular
carcinoma are of limited efficacy. MCT-485, possessing both
oncolytic and immune activating properties, could be superior to
doxorubicin, cisplatin and other currently marketed therapies by
providing a more robust activation of immunity, and a more global
and longer lasting anti-tumor effect.
About MCT-485
MultiCell Technologies' MCT-485 is a noncoding double stranded
micro RNA (miRNA), and the first of a family of prospective cancer
therapeutics. MultiCell owns rights to several issued U.S.
and foreign patents and patent applications related to MCT-485 and
other miRNAs.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage
biopharmaceutical company developing novel therapeutics and
discovery tools for the treatment of neurological disorders,
hepatic disease and cancer. For more information about
MultiCell Technologies, please visit
http://www.multicelltech.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell's
expectations, beliefs, plans, objectives, assumptions or future
events or performance are not historical facts and are
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"). These statements
are often, but not always, made through the use of words or phrases
such as "believe", "will", "expect", "anticipate", "estimate",
"intend", "plan", "forecast", "could", and "would". MultiCell bases
these forward- looking statements on current expectations about
future events. They involve known and unknown risks,
uncertainties and assumptions that may cause actual results, levels
of activity, performance or achievements to differ materially from
those expressed or implied by any forward-looking statement.
Some of the risks, uncertainties and assumptions that could cause
actual results to differ materially from estimates or projections
in the forward-looking statement include, but are not limited to,
the risk that we might not achieve our anticipated clinical
development milestones, receive regulatory approval, or
successfully commercialize our products as expected, the market for
our products will not grow as expected, and the risk that our
products will not achieve expectations. For additional
information about risks and uncertainties MultiCell faces, see
documents that MultiCell files with the Securities and Exchange
Commission, including MultiCell's report on Form 10-K for the
fiscal year ended November 30, 2012,
and all of MultiCell's quarterly and other periodic SEC
filings. MultiCell claims the protection of the safe harbor
for forward-looking statements under the Act and assumes no
obligation and expressly disclaims any duty to update any
forward-looking statement to reflect events or circumstances after
the date of this news release or to reflect the occurrence of
subsequent events.
SOURCE MultiCell Technologies, Inc.